Intravenous immunoglobulins (IVIg) in the treatment of multiple sclerosis;Traitement par immunoglobulines intraveineuses (IgIV) de la sclerose en plaques

Annales de Medecine Interne

Volumn 151, Issue SUPPL. 1, 2000, Pages

  Achiron, Anat ^a   Miron, Shmuel ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

Intravenous immunoglobulins; IVIg; Multiple sclerosis

Indexed keywords

BETA INTERFERON; IMMUNOGLOBULIN;

HUMAN; MULTIPLE SCLEROSIS; NEURORADIOLOGY; NONHUMAN; REVIEW;

DISEASE PROGRESSION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECURRENCE;

EID: 0343526765     PISSN: 0003410X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. COMPSTON A, EBERS G, LASSMANN H, MCDONALD I, MATTHEWS B, WEKERLE H. McAlpine's multiple sclerosis. London: Churchill Livingstone, 1998.
2. KURTZKE JF, BEEBE GW, NAGLER B, KURLAND LT, AUTH TL. Studies on the natural history of multiple sclerosis. Early prognostic features of the later course of the illness. J Chronic Dis, 1977; 30: 819-30.
3. HICKEY WF. The pathology of multiple sclerosis: a historical perspective. J Neuroimmunol, 1999; 98: 37-44.
4. TRAPP BD, BO L, MORK S, CHANG A. Pathogenesis of tissue injury in MS lesions. J Neuroimmunol, 1999; 98: 49-56.
5. CICCARELLI O, GIUGNI E, PAOLILLO A et al. Magnetic resonance outcome of new enhancing lesions in patients with relapsing-remitting multiple sclerosis. Eur J Neurol, 1999; 6: 455-9.
6. ACHIRON A, PRAS E, GILAD R, et al. Open controlled therapeutic trial of high-dose intravenous immunoglobulins in relapsing-remitting multiple sclerosis. Arch Neurol, 1992; 49: 1233-6.
7. ACHIRON A, GABBAY U, GILAD R, et al. Intravenous Immunoglobulin treatment in multiple sclerosis. Effects on relapses. Neurology, 1998; 50: 398-402.
8. FAZLKAS F, DEISENHAMMER F, STRASSER-FUCHS S, NAHLER G, MAMOLI B. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet, 1997; 349: 589-93.
9. SORENSEN PS, WANSCHER B, JENSEN CV, et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology, 1998; 50: 1273-81.
10. POSER CM, PATY DW, SCHEINBERG L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol, 1983; 13: 227-31.
11. KURTZKE JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology, 1983; 33: 1444-52.
12. RUDICK RA. Disease-modifying drugs for relapsing-remitting multiple sclerosis and future directions for multiple sclerosis therapeutics. Arch Neurol, 1999; 56: 1079-84.
13. JACOBS LD, COOKFAIR DL, RUDICK RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol, 1996; 39: 285-94.
14. POZZILLI C, BASTIANELLO S, KOUDRIAVTSEVA T, et al. Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry, 1996; 61: 251-8.
15. ACHIRON A. Complications of intravenous immune globulin treatment in neurologic disease. Neurology, 1997; 49: 899-900.
16. ACHIRON A, MARGALIT R, HERSHKOVIZ R, et al. Intravenous immunoglobulin treatment of experimental T-cell mediated autoimmune diseases: Up-regulation of T cell proliferation and down-regulation of TNF-aα secretion. J Clin Invest, 1994; 93: 600-5.
17. BEN-NUN A, COHEN IR. Experimental autoimmune encephalomyelitis (EAE) mediated by T cell lines: process of selection of lines and characterization of the cells. J Immunol, 1982; 129: 303-8.
18. ACHIRON A, MOR F, MARGALIT R, COHEN IR, LIDER O, MIRON S. Suppression of experimental autoimmune encephalomyelitis by intravenously administrated polyclonal immunoglobulins (In preparation).
19. LUZI G, FERRARA R. Immunoregulation of autoimmune disorders: the role of intravenous immunoglobulins. Int J Artif Organs, 1993; 16(Suppl 5): 189-95.
20. MOUTHON L, HUREZ V, KAZATCHKINE M. Mechanisms of action of intravenous immunoglobulins in the treatment of autoimmune diseases. Ann Med Interne, 1993; 144: 506-13.
21. PASHOV A, DUBEY C, KAVERI SV, et al. Normal immunoglobulin G protects against experimental allergic encephalomyelitis by inducing transferable T cell unresponsiveness to myelin basic protein. Eur J Immunol, 1998; 28: 1823-31.
22. STANGEL M, TOYKA KV, GOLD R. Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases. Arch Neurol, 1999; 56: 661-3.
23. NOSEWORTHY J, OQBRIEN P, VAN ENGELEN B, RODRIGUEZ M. Intravenous immunoglobulin therapy in multiple sclerosis: progress from remyelination in the Theiler's virus model to a randomised, double-blind, placebo-controlled clinical trial. J Neurol Neurosurg Psychiatry, 1994; 57(Suppl): 11-4.